Johnson & Johnson (JNJ) Units to Pay $65 Million in Tracleer Antitrust Class Action Settlement, Reuters Reports

Core Insights - Johnson & Johnson (NYSE: JNJ) is involved in a $65 million antitrust class action settlement related to its pulmonary hypertension drug Tracleer, which allegedly delayed competition for a generic version of the medication [2] - The company operates through two main segments: Innovative Medicine, focusing on therapeutic areas such as oncology and immunology, and MedTech, which includes a wide range of medical devices [3] Group 1 - Johnson & Johnson units have agreed to pay $65 million to settle claims from health plans alleging overcharging for Tracleer [2] - The lawsuit claimed that Johnson & Johnson obstructed competitor access to Tracleer samples, hindering the market entry of generic alternatives [2] - Actelion Pharmaceuticals, which developed Tracleer and was acquired by Johnson & Johnson in 2017, reportedly made billions in profits from the drug [2] Group 2 - The Innovative Medicine segment of Johnson & Johnson focuses on various therapeutic areas, including oncology, infectious diseases, and cardiovascular diseases [3] - The MedTech segment encompasses a diverse range of medical devices used in fields such as cardiovascular intervention and orthopedics [3]